Form 4: BVF Partners Reports Transactions in Eledon Pharmaceuticals, Inc. Securities

BVF Partners and affiliated entities report transactions involving common stock, pre-funded warrants, convertible preferred stock, and warrants of Eledon Pharmaceuticals, Inc.

Summary

• BVF Partners L.P., along with affiliated entities, filed a Form 4 detailing changes in beneficial ownership of Eledon Pharmaceuticals, Inc. securities.
• The reporting persons include Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF I GP LLC, BVF II GP LLC, BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert.
• The reported transactions involve common stock, pre-funded warrants to purchase common stock, Series X Convertible Preferred Stock, Series X1 Convertible Preferred Stock, warrants to purchase common stock, and warrants to purchase Series X1 Convertible Preferred Stock.
• The reporting persons collectively own over 10% of Eledon Pharmaceuticals' outstanding common stock but disclaim beneficial ownership except to the extent of their pecuniary interest.
• The pre-funded warrants are immediately exercisable but cannot be exercised if the reporting persons would exceed a 9.99% ownership threshold.
• Series X and X1 Convertible Preferred Stock also have exercise limitations based on a 9.99% ownership cap.
• Some warrants were issued pursuant to warrant exercise and purchase agreements, with exercise prices adjusted due to a reverse stock split.
• The warrants have various expiration dates and are subject to adjustments for stock splits and similar events.
• The reporting persons have pre-funded warrants to purchase common stock at an exercise price of $0.001 per share, expiring on December 31, 2030.
• Common warrants are immediately exercisable with a five-year term, also subject to the 9.99% ownership limitation.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing securities transactions. It doesn't inherently convey positive or negative sentiment.

Risks

• The reporting persons' ability to exercise warrants and convertible preferred stock is limited by a 9.99% ownership cap, which could restrict their potential gains.
• Adjustments to exercise prices and conversion ratios due to stock splits or other events could impact the value of the securities held by the reporting persons.

Industry Context

This filing is a routine disclosure of securities transactions by a major shareholder in a publicly traded company, which is common in the biotechnology industry where institutional investors often hold significant positions.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders, as mandated by the SEC.
• The 9.99% ownership limitation is a common provision in warrants and convertible securities to avoid triggering certain regulatory thresholds and obligations.
• Reverse stock splits are often used by companies to increase their stock price and maintain listing requirements, which can impact the terms of outstanding warrants and convertible securities.

Stakeholder Impact

• The transactions reported may influence investor perception of Eledon Pharmaceuticals, potentially affecting the stock price.
• The ownership stake of BVF Partners and affiliated entities is significant, making their investment decisions relevant to other shareholders.

Key Dates